U. S. Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended March 31, 2004

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

     For the transition period from                  to
                                    -----------------   ---------------

                       Commission File No. 000-49655
                                           ---------


                         LIPIDVIRO TECH, INC.
                         -----------------------
     (Exact Name of Small Business Issuer as specified in its Charter)


            Nevada                                     87-0678927
             ----                                      ----------
  (State or Other Jurisdiction of                (I.R.S. Employer I.D. No.
incorporation or organization)

                        2120 South 700 East, #H183
                        Salt Lake City, Utah 84106
                        --------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (801) 583-9900
                                            --------------

             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                                     N/A

     Check whether the registrant filed all documents and reports required to
be filed by Section 12, 13, or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.  Yes    No

                   APPLICABLE ONLY TO CORPORATE ISSUERS

     State the number of shares outstanding of each of the Registrant's
classes of common equity, as of the latest practicable date:

                            March 31, 2004

               Common Voting Stock   10,031,863 shares

Transitional Small Business Disclosure Format (Check one):  Yes X   No

ITEM 1 Financial Information

     The Financial Statements of the Company required to be filed with
this 10-QSB Quarterly Report were prepared by management, and commence on the
following page, together with Related Notes.  In the opinion of management,
the Financial Statements fairly present the financial condition of the
Company.
<PAGE>

               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

      UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                          MARCH 31, 2004
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]




                             CONTENTS

                                                                   PAGE

     Unaudited Condensed Consolidated Balance
          Sheets, March 31, 2004 and December 31, 2003               2

     Unaudited Condensed Consolidated Statements of
          Operations, for the three months ended
          March 31, 2004 and from inception on May 6,
          2003 through March 31, 2004                                3


     Unaudited Condensed Consolidated Statements of
          Cash Flows, for the three months ended
          March 31, 2004 and from inception on May 6,
          2003 through March 31, 2004                                4

     Notes to Unaudited Condensed Consolidated
               Financial Statements                             5 - 12
<PAGE>
<TABLE>
<CAPTION>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

         UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

                              ASSETS
                                                   March 31,    December 31,
                                                     2004           2003
                                                  ___________    ___________
<S>                                             <C>            <C>
CURRENT ASSETS:
     Cash                                        $      3,789   $      3,702
     Prepaid expense                                    5,058          3,919
                                                  ___________    ___________
               Total Current Assets                     8,847          7,621
                                                  ___________    ___________

PROPERTY AND EQUIPMENT, net                             2,963          2,118
                                                  ___________    ___________

OTHER ASSETS:
     Definite-life intangible assets, net               3,826              -
     Goodwill                                         290,317        269,006
                                                  ___________    ___________
               Total Other Assets                     294,143        269,006
                                                  ___________    ___________
                                                  $   305,953    $   278,745
                                                  ___________    ___________

               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
     Accounts payable                             $    39,174    $    26,387
     Shareholder advances                              95,000         65,000
                                                  ___________    ___________
               Total Current Liabilities              134,174         91,387
                                                  ___________    ___________

STOCKHOLDERS' EQUITY [Restated]:
     Common stock, $.001 par value,
          150,000,000 shares authorized,
          10,031,862 and 9,818,750 shares
          issued and outstanding, respectively         10,032          9,819
     Capital in excess of par value                   344,352        323,254
     Deficit accumulated during the
          development stage                          (182,605)      (145,715)
                                                  ___________    ___________
          Total Stockholders' Equity                  171,779        187,358
                                                  ___________    ___________

                                                  $   305,953    $   278,745
                                                  ___________    ___________
</TABLE>
Note: The balance sheet at December 31, 2003 was taken from the audited
          financial statements at that date and condensed.

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
                                2
<PAGE>
<TABLE>
<CAPTION>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


                                                            From Inception
                                             For the Three  on May 6, 2003
                                             Months Ended       Through
                                            March 31, 2004   March 31, 2004
                                              ____________   ____________
<S>                                        <C>             <C>
REVENUE                                     $          -   $          -

EXPENSES:
     General and administrative                   12,097         92,254
     Research and development                     24,793         90,351
                                            ____________   ____________
          Total Expenses                          36,890        182,605
                                            ____________   ____________

LOSS BEFORE INCOME TAXES                         (36,890)      (182,605)

CURRENT TAX EXPENSE (BENEFIT)                          -              -

DEFERRED TAX EXPENSE (BENEFIT)                         -              -
                                            ____________   ____________

NET LOSS                                    $    (36,890)  $   (182,605)
                                            ____________   ____________

LOSS PER COMMON SHARE                       $       (.00)  $       (.02)
                                            ____________   ____________

</TABLE>

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
                                3
<PAGE>
<TABLE>
<CAPTION>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


                                                            From Inception
                                             For the Three  on May 6, 2003
                                             Months Ended       Through
                                            March 31, 2004   March 31, 2004
                                              ____________   ____________
<S>                                        <C>             <C>
Cash Flows from Operating Activities:
     Net loss                                 $    (36,890)  $   (182,605)
     Adjustments to reconcile net loss to net
       cash used by operating activities:
          Depreciation expense                         115            300
          Non-cash expenses paid by issuance
          of common stock                                -            750
          Non-cash services paid by issuance
          of common stock                                -            113
          Changes in assets and liabilities:
               (Increase) in prepaid expense        (1,139)        (5,058)
               Increase in accounts payable         12,787         39,174
                                              ____________   ____________
                         Net Cash (Used) by
                         Operating Activities      (25,127)      (147,326)
                                              ____________   ____________
Cash Flows from Investing Activities:
     Payments for property and equipment              (960)        (3,263)
     Payments for definite-life intangible assets   (3,826)        (3,826)
     Payments for goodwill                               -       (269,006)
                                              ____________   ____________
                         Net Cash (Used) by
                         Investing Activities       (4,786)      (276,095)
                                              ____________   ____________
Cash Flows from Financing Activities:
     Proceeds from shareholder advances             30,000         95,000
     Proceeds from issuance of common stock              -        293,700
     Proceeds from sale of warrants                      -         38,510
                                              ____________   ____________
                         Net Cash Provided by
                         Financing Activities       30,000        427,210
                                              ____________   ____________
Net Increase (Decrease) in Cash                         87          3,789

Cash at Beginning of Period                          3,702              -
                                              ____________   ____________
Cash at End of Period                         $      3,789   $      3,789
                                              ____________   ____________
Supplemental Disclosures of Cash Flow Information:
     Cash paid during the period for:
       Interest                               $          -   $          -
       Income taxes                           $          -   $          -

Supplemental Schedule of Non-cash Investing and Financing Activities:
     For the period from inception on May 6, 2003 through March 31, 2004:
     In January 2004, the Company issued 213,112 shares of common stock as
     part of a downstream merger [See Note 2].

     In June 2003, the Company issued 3,750 shares of common stock for
     services rendered valued at $113.

     In May 2003, the Company issued 25,000 shares of common stock as
     repayment of organization costs of $750.
</TABLE>
The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.
                                4
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     Organization - LipidViro Tech, Inc. ("Parent") was organized under the
     laws of the State of California on October 19, 1954 as Anticline
     Uranium, Inc.  In October 2001, Parent changed its domicile from
     California to Nevada by merging with and into a wholly owned subsidiary
     with the same name and the Nevada entity being the surviving entity.  In
     January 2004, Parent changed its name to LipidViro Tech, Inc.  On June
     24, 2003, Subsidiary acquired 95.9% of the outstanding stock of Parent
     pursuant to a Share Purchase Agreement.  The agreement called for
     Subsidiary to pay $65,718 to the former shareholders of Parent for
     5,000,000 shares of Parent's common stock wherein Parent became a 95.9%
     owned subsidiary of Subsidiary [See Note 3].  On January 14, 2004,
     Parent issued 9,818,750 shares of its common stock for all 9,818,750
     outstanding shares of Subsidiary's common stock wherein Subsidiary
     became a wholly owned subsidiary of Parent in a transaction which has
     been accounted for as a downstream merger [See Note 2].  Accordingly,
     the equity transactions have been restated to reflect the
     recapitalization of Subsidiary and the operations of Parent prior to
     June 24, 2003 have been eliminated.  The financial statements reflect
     the operations of Subsidiary from its inception.

     Lipidviro Tech Inc. ("Subsidiary") was organized under the laws of the
     State of Utah on May 6, 2003.

     LipidViro Tech, Inc. and Subsidiary ("the Company") plans to research
     and market substances and compounds for antiviral and antibacterial
     purposes.  The Company has not generated any revenues from their planned
     principal operations and is considered a development stage company as
     defined in Statement of Financial Accounting Standards No. 7.  The
     Company has, at the present time, not paid any dividends and any
     dividends that may be paid in the future will depend upon the financial
     requirements of the Company and other relevant factors.

     Condensed Financial Statements - The accompanying financial statements
     have been prepared by the Company without audit.  In the opinion of
     management, all adjustments (which include only normal recurring
     adjustments) necessary to present fairly the financial position, results
     of operations and cash flows at March 31, 2004 and for the periods then
     ended have been made.

     Certain information and footnote disclosures normally included in
     financial statements prepared in accordance with generally accepted
     accounting principles in the United States of America have been
     condensed or omitted.  It is suggested that these condensed financial
     statements be read in conjunction with the financial statements and
     notes thereto included in the Company's December 31, 2003 audited
     financial statements.  The results of operations for the periods ended
     March 31, 2004 are not necessarily indicative of the operating results
     for the full year.

     Consolidation - The consolidated financial statements include the
     accounts of Parent and Parent's wholly owned Subsidiary.  All
     significant intercompany transactions have been eliminated in
     consolidation.

     Cash and Cash Equivalents - The Company considers all highly liquid debt
     investments purchased with a maturity of three months or less to be cash
     equivalents.
                                5
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Continued]

     Property and Equipment - Property and equipment are stated at cost.
     Expenditures for major renewals and betterments that extend the useful
     lives of property and equipment are capitalized upon being placed in
     service.  Expenditures for maintenance and repairs are charged to
     expense as incurred.  Depreciation is computed using the straight-line
     method over the estimated useful lives of the assets of five years.  In
     accordance with Statement of Financial Accounting Standards No. 144,
     "Accounting for the Impairment or Disposal of Long-Lived Assets", the
     Company periodically reviews their property and equipment for
     impairment.

     Website Costs - The Company has adopted the provisions of Emerging
     Issues Task Force 00-2, "Accounting for Web Site Development Costs."
     Costs incurred in the planning stage of a website are expensed as
     research and development while costs incurred in the development stage
     are capitalized and amortized over the life of the asset, estimated to
     be five years.  As of March 31, 2004, the Company has capitalized a
     total of $2,830 of website costs which are included in property and
     equipment.  The Company did not incur any planning costs and did not
     record any research and development costs for the three months ended
     March 31, 2004.

     Intangible Assets - The Company accounts for their intangible assets in
     accordance with Statement of Financial Accounting Standards No. 142,
     "Goodwill and Other Intangible Assets".  SFAS No. 142 establishes three
     classifications for intangible assets including definite-life intangible
     assets, indefinite-life intangible assets and goodwill and requires
     different accounting treatment and disclosures for each classification.
     In accordance with SFAS No. 142, the Company periodically reviews their
     intangible assets for impairment.  No impairment was recorded during the
     three months ended March 31, 2004.

     Research and Development - Research and development costs are expensed
     as incurred.  The Company expensed $24,793 in research and development
     costs during the three months ended March 31, 2004.

     Income Taxes - The Company accounts for income taxes in accordance with
     Statement of Financial Accounting Standards No. 109 "Accounting for
     Income Taxes" [See Note 8].

     Minority Interest - From June 24, 2003 through January 14, 2004,
     Subsidiary owned 95.9% of Parent.  The net loss of Parent applicable to
     the non-controlling minority interest was not allocated to the minority
     interests as there was no obligation of the non-controlling minority
     interests to share in such losses.  On January 14, 2004, Subsidiary
     acquired the minority interest in a downstream merger [See Note 2].

     Loss Per Share - The computation of loss per share is based on the
     weighted average number of shares outstanding during the period
     presented in accordance with Statement of Financial Accounting Standards
     No. 128, "Earnings Per Share" [See Note 11].
                                6
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]
  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Continued]

     Accounting Estimates - The preparation of financial statements in
     conformity with generally accepted accounting principles in the United
     States of America requires management to make estimates and assumptions
     that affect the reported amounts of assets and liabilities, the
     disclosures of contingent assets and liabilities at the date of the
     financial statements, and the reported amount of revenues and expenses
     during the reported period.  Actual results could differ from those
     estimated.

     Recently Enacted Accounting Standards - Statement of Financial
     Accounting Standards ("SFAS") No. 146, "Accounting for Costs Associated
     with Exit or Disposal Activities", SFAS No. 147, "Acquisitions of
     Certain Financial Institutions - an Amendment of FASB Statements No. 72
     and 144 and FASB Interpretation No. 9", SFAS No. 148, "Accounting for
     Stock-Based Compensation - Transition and Disclosure - an Amendment of
     FASB Statement No. 123", SFAS No. 149, "Amendment of Statement 133 on
     Derivative Instruments and Hedging Activities", and SFAS No. 150,
     "Accounting for Certain Financial Instruments with Characteristics of
     both Liabilities and Equity", were recently issued.  SFAS No. 146, 147,
     148, 149 and 150 have no current applicability to the Company or their
     effect on the financial statements would not have been significant.

     Reclassification - The financial statements for periods prior to March
     31, 2004 have been reclassified to conform to the headings and
     classifications used in the March 31, 2004 financial statements.

     Restatement - The financial statements have been restated for all
     periods presented to reflect the recapitalization of Subsidiary [See
     Note 2] and to reflect a 1-for-100 reverse stock split that Parent
     effected on October 4, 2001 and a 4-for-1 forward stock split that
     Parent effected on December 31, 2001 [See Note 7].

NOTE 2 - DOWNSTREAM MERGER

     On January 14, 2004, Subsidiary acquired the minority interests in
     Parent and Subsidiary was reorganized as a subsidiary of Parent in a
     transaction in which Parent issued 9,818,750 shares of its common stock
     in exchange for all 9,818,750 outstanding shares of Subsidiary's common
     stock.  Accordingly, the equity transactions have been restated to
     reflect the recapitalization of Subsidiary.  The Company recorded
     goodwill of $21,311 as a result of the downstream merger.  The financial
     statements reflect the operations of Subsidiary from its inception.  As
     part of the downstream merger, Parent issued 1,915,000 Class A warrants
     and 1,915,000 Class B warrants to replace similar warrants of
     Subsidiary.  Parent also cancelled 5,000,000 shares of its common stock
     which had previously been owned by Subsidiary.
                                7
<PAGE>

               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3 - ACQUISITION OF 95.9% OF LIPIDVIRO TECH, INC.

     On June 24, 2003, Subsidiary acquired 95.9% of the outstanding stock of
     Parent pursuant to a Share Purchase Agreement.  The agreement called for
     Subsidiary to pay $65,718 to the former shareholders of Parent for
     5,000,000 shares of Parent's common stock wherein Parent became a 95.9%
     owned subsidiary of Subsidiary.  The agreement also called for
     Subsidiary to advance an additional $203,282 to pay costs associated
     with the acquisition and to reduce the liabilities of Parent.  The
     acquisition closed June 24, 2003 and has been accounted for as a
     purchase of Parent.  The Company recorded goodwill of $269,006 as a
     result of the acquisition.  The financial statements reflect the
     operations of Parent from June 24, 2003.

NOTE 4 - PROPERTY AND EQUIPMENT

     Property and equipment consisted of the following at:

                                                 March 31,   December 31,
                                                   2004         2003
                                               ___________   ___________
     Office equipment                          $       433   $       433
     Website                                         2,830         1,870
                                               ___________   ___________
                                                     3,263         2,303

     Less: accumulated depreciation                   (300)         (185)
                                               ___________   ___________
     Net property and equipment                $     2,963   $     2,118
                                               ___________   ___________

     Depreciation expense for the three months ended March 31, 2004 was $115.

NOTE 5 - DEFINITE-LIFE INTANGIBLE ASSETS

     Definite-life intangible assets consist of the following at:

                                                 March 31,   December 31,
                                                   2004         2003
                                               ___________    ___________
          Patent applications in process       $    3,826     $         -

          Less: Accumulated amortization                -               -
                                               __________     ___________
          Net Definite-life Intangible Assets  $    3,826     $         -
                                               __________     ___________

     The Company's definite-life intangible assets are amortized, upon being
     placed in service, over the estimated useful lives of the assets of 20
     years with no residual value.  Amortization expense for the three months
     ended March 31, 2004 was $0.  The Company estimates that their
     amortization expense for each of the next five years will be
     approximately $200 per year.
                                8
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - GOODWILL

     The Company has no indefinite-life or definite-life intangible assets.
     The following is a summary of the transactions affecting the Company's
     goodwill.


                                                            From Inception
                                             For the Three  on May 6, 2003
                                             Months Ended       Through
                                            March 31, 2004   March 31, 2004
                                              ____________   ____________
          Goodwill at beginning of period     $    269,006   $          -

          Goodwill from the acquisition of
            95.9% of Parent                              -        269,006

          Goodwill from the acquisition of
            the minority interests in Parent        21,311         21,311
                                              ____________   ____________

          Goodwill at end of period           $    290,317   $    290,317
                                              ____________   ____________

NOTE 7 - CAPITAL STOCK

     Common Stock - The Company has authorized 150,000,000 shares of common
     stock with a par value of $.001.

     In January 2004, the Company issued 213,112 shares of their previously
     authorized but unissued common stock to the former shareholders of
     Subsidiary as part of a downstream merger [See Note 2].

     In June 2003, the Company issued 3,750 shares of their previously
     authorized but unissued common stock to an officer of the Company for
     services rendered valued at $113, or $.03 per share.

     In June 2003, the Company issued 7,875,000 shares of their previously
     authorized but unissued common stock for cash of $236,250, or .03 per
     share.

     In May 2003, the Company issued 1,915,000 units.  Each unit consisted of
     one share of the Company's previously authorized but unissued common
     stock, one Class A warrant and one Class B warrant.  The units were
     issued for cash of $95,960, or approximately $.05 per unit.

     In May 2003, in connection with their organization, the Company issued
     25,000 shares of their previously authorized but unissued common stock
     to an officer of the Company as repayment of organization costs of $750,
     or $.03 per share.

     Stock Splits - On December 31, 2001, Parent effected a 4-for-1 forward
     stock split.  On October 4, 2001, Parent effected a 1-for-100 reverse
     stock split.  The financial statements for all periods presented have
     been restated to reflect these stock splits.
                                9
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK [Continued]

     Class A Warrants - In May 2003, the Company issued 1,915,000 Class A
     Warrants for cash of $19,255, or approximately $.01 per warrant, as part
     of a private placement offering.  The warrants vested immediately and
     are exercisable at $5.00 per share.  The warrants were originally
     exercisable for two years.  In August 2003, the Company changed the
     exercise period so the warrants are only exercisable during June 2006.
     At March 31, 2004, none of these warrants had been exercised, forfeited
     or cancelled.

     Class B Warrants - In May 2003, the Company issued 1,915,000 Class B
     Warrants for cash of $19,255, or approximately $.01 per warrant, as part
     of a private placement offering.  The warrants vested immediately and
     are exercisable at $10.00 per share.  The warrants were originally
     exercisable for two years.  In August 2003, the Company changed the
     exercise period so the warrants are only exercisable during June 2006.
     At March 31, 2004, none of these warrants had been exercised, forfeited
     or cancelled.

     Stock Option Plan - In March 2003, the Board of Directors of Parent
     approved and adopted the "2003 Stock Option/Stock Issuance Plan" ("the
     Plan") with a maximum of 1,500,000 shares of common stock reserved for
     issuance under the Plan.  The Plan provides for both the direct award of
     shares and for the grant of options to purchase shares.  The Board of
     Directors has authorized options to purchase 500,000 common shares to be
     granted at a purchase price of $0.01 per share, but to date the Company
     has not granted any options to their employees, officers or directors.
     Under the Plan, the Board of Directors shall determine which eligible
     persons are to receive Incentive Options, Non-Statutory grants or stock
     issuances.  The Board of Directors also sets the exercise price for
     options granted.  The option terms are not to exceed ten years from the
     option grant date.  At March 31, 2004, total awards available to be
     granted from the Plan amounted to 1,500,000.

NOTE 8 - INCOME TAXES

     The Company accounts for income taxes in accordance with Statement of
     Financial Accounting Standards No. 109 "Accounting for Income Taxes".
     SFAS No. 109 requires the Company to provide a net deferred tax
     asset/liability equal to the expected future tax benefit/expense of
     temporary reporting differences between book and tax accounting methods
     and any available operating loss or tax credit carryforwards.  The
     Company has available at March 31, 2004 unused operating loss
     carryforwards of approximately $239,000 which may be applied against
     future taxable income and which expire in various years through 2024.
     Due to substantial changes in the Company's ownership, there will be an
     annual limitation on the amount of net operating loss carryforwards
     which can be utilized.
                                10
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                   [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 - INCOME TAXES [Continued]

     The amount of and ultimate realization of the benefits from the
     operating loss carryforwards for income tax purposes is dependent, in
     part, upon the tax laws in effect, the future earnings of the Company,
     and other future events, the effects of which cannot be determined.
     Because of the uncertainty surrounding the realization of the deferred
     tax assets, the Company has established a valuation allowance equal to
     the tax effect of the loss carryforwards, therefore, no deferred tax
     asset has been recognized.  The net deferred tax assets, which consist
     of difference in book and tax basis of fixed assets and net operating
     losses, are approximately $48,000 and $38,400 as of March 31, 2004 and
     December 31, 2003, respectively, with an offsetting valuation allowance
     of the same amount, resulting in a change in the valuation allowance of
     approximately $9,600 during the three months ended March 31, 2004.

NOTE 9 - RELATED PARTY TRANSACTIONS

     Management Compensation - The Company has not paid any cash compensation
     to any officer or director of the Company.  However, in June 2003, the
     Company issued 3,750 shares of common stock to an officer of the Company
     for services rendered valued at $113 [See Note 7].

     Office Space - The Company has not had a need to rent office space.  A
     shareholder (former officer) of the Company is allowing the Company to
     use her mailing address, as needed, at no expense to the Company.

     Stock Issuance - In May 2003, in connection with their organization, the
     Company issued 25,000 shares of their previously authorized but unissued
     common stock to an officer of the Company as repayment of organization
     costs of $750, or $.03 per share.

     Shareholder Advances - During the three months ended March 31, 2004, a
     shareholder of the Company advanced $30,000 to the Company.  At March
     31, 2004, the Company owes a total of $95,000 to the shareholder.  The
     shareholder has agreed to advance up to $100,000 to the Company.  The
     advances bear no interest and are due December 31, 2004.

NOTE 10 - GOING CONCERN

     The accompanying financial statements have been prepared in conformity
     with generally accepted accounting principles in the United States of
     America, which contemplate continuation of the Company as a going
     concern.  However, the Company was only recently formed and has not yet
     been successful in establishing profitable operations.  Further, the
     Company has current liabilities in excess of current assets.  These
     factors raise substantial doubt about the ability of the Company to
     continue as a going concern.  In this regard, management is proposing to
     raise any necessary additional funds not provided by operations through
     loans or through additional sales of their common stock.  There is no
     assurance that the Company will be successful in raising this additional
     capital or in achieving profitable operations.  The financial statements
     do not include any adjustments that might result from the outcome of
     these uncertainties.
                                11
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 - LOSS PER SHARE

     The following data shows the amounts used in computing loss per share:


                                                            From Inception
                                             For the Three  on May 6, 2003
                                             Months Ended       Through
                                            March 31, 2004   March 31, 2004
                                              ____________   ____________
          Loss from continuing operations
          available to common
          shareholders (numerator)           $    (36,890)  $   (182,605)
                                             ____________   ____________
          Weighted average number of
          common shares outstanding
          used in loss per share for the
          period (denominator)                  9,999,076      8,939,340
                                             ____________   ____________

     At March 31, 2004, the Company had 1,915,000 Class A warrants and
     1,915,000 Class B warrants outstanding which were not used in the
     computation of dilutive loss per share because their effect would be
     anti-dilutive.  Dilutive loss per share was not presented, as the
     Company had no common stock equivalent shares for all periods presented
     that would effect the computation of diluted loss per share.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

     Agreements - In October 2003, the Company signed one-year agreements for
     the use of a research facility and staff to conduct research on behalf
     of the Company and to have a researcher coordinate the activities.  The
     Company will pay up to $76,325 for supplies, facilities, a laboratory
     technician and coordination efforts.

     Possible Claims Related to Previously Leased Mining Property - In August
     2001, Parent obtained 96.5% of the rights to certain mining claims in
     the Tintic Mining District of Juab County, Utah under the terms of a 5-
     year Mining Lease.  Under the terms of the lease, Parent was obligated
     to spend $15,000 over the term of the lease for exploration, mining,
     development or similar costs for the benefit of the property subject to
     the lease.  Parent was also obligated to pay a 3.5% net smelter royalty
     on all mineral-bearing ores sold.  The lease also gave a credit to
     Parent for the first $30,000 of net smelter royalties.  The lessor also
     agreed to indemnify and hold Parent harmless from any Environmental
     Protection Agency claim or claims by a similar state agency based solely
     on past mining contaminations or other environmental violations or
     damage.  In June 2003, Parent paid $3,459 to cancel the Mining Lease.
     The Company's management believes that the Company would not be
     responsible for any future claims against the property which Parent
     previously leased, but the possibility exists that claims may arise
     against the property and the Company may be named in such claims based
     on the previous leasing arrangements.  The Company's management believes
     that the Company would be successful in defending against any such
     claims that may arise.  No accrual for possible losses or settlements
     has been recorded in the accompanying financial statements.
                                12
<PAGE>

ITEM 2 Management Discussions and Analysis or Plan of Operation

Plan of Reorganization
----------------------

          On June 24, 2003, a Share Purchase Agreement (the Agreement") was
executed by and between North Beck Joint Venture, LLC, a Utah limited
liability company ("North Beck"), that was the owner of approximately 96% of
the outstanding voting securities of the Company, as "Seller," and
LipidViro Tech, Inc., a privately-held Utah corporation ("LipidViro-Utah"), as
"Buyer."  Pursuant to the terms of the Agreement, LipidViro-Utah acquired
5,000,000 shares of the Company's common stock, or approximately 96% of its
outstanding voting  securities.  See the 8-K Current Report of the Company
dated June 24, 2003, which was previously filed with the Securities and
Exchange Commission on June 27, 2003, and which is incorporated herein by
reference.  See Item 6.

          The Company and LipidViro-Utah entered into an Agreement and Plan of
Reorganization (the "Reorganization Agreement"), a copy of which was attached
to the 8-K Current Report filed with the Securities and Exchange
Commission on September 9, 2003, and which is incorporated by reference, by
which LipidViro-Utah was to be acquired as a wholly-owned subsidiary of the
Registrant.  See Item 6.

          On August 19, 2003, LipidViro-Utah filed a Petition for Fairness
Hearing and a Motion for Expedited Hearing in the Third Judicial District
Court in and for Salt Lake County, State of Utah, respecting the
Reorganization Agreement, copies of which were also attached to the 8-K
Current Report filed with the Securities and Exchange Commission on September
9, 2003.  The Petition for Fairness Hearing was filed because of the 95%
ownership of the Company by LipidViro-Utah and the fact that following the
closing of the Agreement with North Beck, the directors and executive officers
of LipidViro-Utah had been designated to serve as directors and executive
officers of the Company too.  See Item 7.  The Fairness Hearing was requested
in order for LipidViro-Utah's shareholders to receive the contemplated
issuance of securities under the Reorganization Agreement in accordance with
United States and Utah securities laws, and pursuant to the exemption from
registration provided in Section 3(a)(10) of the Securities Act of 1933, as
amended ("the Securities Act").  The Fairness Hearing was held on September 8,
2003, and the Court took LipidViro Utah's Petition under advisement, after
hearing oral argument, with the Court eventually deferring to the Utah
Division of Securities to conduct the Fairness Hearing, based upon the recent
adoption of an amendment to Section 61-1-11.1 of the Utah Uniform Securities
Act that granted the Utah Division of Securities authority to conduct such
hearings.  With (i) the Company being a Nevada corporation, (ii) there being
some question as to whether the Company or LipidViro-Utah should petition for
the Fairness Hearing and (iii) the Utah Division of Securities having not
formally adopted rules and regulations to implement such hearings, the Company
filed another Petition for Fairness Hearing in the Fourth Judicial District
Court of the State of Nevada, in and for the County of Elko, for a Fairness
Hearing on the Reorganization Agreement.

          The principal terms of the Reorganization Agreement were:

     1.   The LipidViro-Utah shareholders would deliver all of the LipidViro-
Utah securities held by LipidViro-Utah shareholders which shares and warrants
shall represented all of the issued and outstanding shares of LipidViro-Utah
common stock and "A" and "B" warrants, and the Company agreed to acquire such
securities in exchange for an aggregate of 9,818,750 shares of the Company's
common stock, par value $0.001 per share, for the LipidViro-Utah common stock,
and 1,915,000 "A" warrants and 1,915,000 "B" like warrants of the Registrant
for the LipidViro-Utah warrants.

     2.   At the closing, the 5,000,000 shares of common stock of the
Company acquired by LipidViro-Utah from North Beck would be cancelled.

     3.   After giving effect to the Reorganization Agreement, the Company
would own all the issued and outstanding shares of LipidViro-Utah, and
LipidViro-Utah would become a wholly-owned subsidiary of the Company,
operating under the name "LipidViro Tech, Inc." or such other name selected by
the shareholders and management of LipidViro-Utah.

          On January 12, 2004, the Nevada Court conducted a Fairness Hearing
and found that the terms and provisions of the Reorganization Agreement and
the issuance and exchange of the securities of the Company and LipidViro-Utah
contemplated thereunder were fair to the Company's shareholders, based upon
the Company's acceptance of the terms of the Reorganization Agreement and
the information concerning the business and finances of the Company and
LipidViro-Utah, all of which was proffered to the Court by the Company's legal
counsel.

          Copies of the Petition for Fairness Hearing and the Court's Order
Granting Petition of Fairness are attached hereto and incorporated herein by
reference.  See Item 6.

Plan of Operation
-----------------

          We are a development-stage biotechnology company, conducting
research focused on developing drug and biological products to treat
infectious pathogens and disease in which lipids or fat components play a key
role.  We have developed a technology based on a process that utilizes our
lipid-targeting investigational compound LVT3.  LVT3 is produced and delivered
to target pathogens by our proprietary drug production and delivery equipment.
We believe LVT3 and our proprietary process targets the lipids of certain
pathogens rendering them non-infectious.  Utilizing our proprietary process
and LVT3, we have commenced pre-clinical product development research designed
to:  (i) demonstrate the capacity of our technology to inactivate pathogens;
(ii) evaluate the toxicity and potential safety of our process; and (iii)
identify potential products for further development.

          Products we are currently evaluating for development include,
therapeutic treatments for diseases caused by infectious pathogens,
therapeutic treatments for lipid associated diseases and viral free
biologics.  We believe our unique lipid targeting technology has the potential
for inactivating or destroying a range of infectious and lipid rich pathogens,
including, the virus that cause SARS, West Nile, Asian Bird Flu, AIDS,
hepatitis B and C.  Many of the diseases caused by these viruses have
ineffective or poor treatment options.

          Our primary activities since incorporation have been developing drug
production and delivery equipment and conducting research to evaluate and
identify potential drug and biological products utilizing our proprietary
lipid targeting technology.  In addition, we have been performing business,
strategic and financial planning and raising capital.  We currently have no
approved, saleable products or services and we are accordingly, considered to
be a biotechnology company in the development stage.  During the first quarter
of 2004, we funded operations and research from monies advanced from a
shareholder of the company.  We continue to seek long term financing to
support our research and operational activities.

Pre-Clinical Laboratory Research, Product Development.
------------------------------------------------------

          Our pre-clinical, product development research is designed to
evaluate our proprietary technology and process to inactivate various
pathogens including viruses, bacteria and prions.  The purpose of this
research is to evaluate efficacy, toxicity and the ability to deliver LVT3 to
a target pathogen.   Where appropriate, research results will be submitted for
peer review publication. Our pre-clinical product development research is
currently in progress.

          We utilize the results of our pre-clinical research studies to
identify potential products.  Each potential product is ranked for development
priority based on our assessment of the product's prospects for commercial
success. Our evaluation includes studying the efficacy and toxicity of LVT3
in-vitro, the time, expense and anticipated regulatory hurdles likely required
to reach commercialization, and, competition in that product category.

          Early research suggests our proprietary technology and process
possess a capacity to inactivate viruses.  While our research is preliminary
and incomplete, and will require additional research to verify, it does
suggests the potential for multiple products that we believe are worthy of
further investigation.   Product categories we are evaluating include: (i)
processing biologicals for pathogen removal and purification; (ii) developing
therapeutics to treat serious infectious diseases; and, (iii) developing
therapeutics for treating lipid associated diseases.

Equipment Development and Pre-Clinical Research.
------------------------------------------------

          During the first fiscal quarter of 2004, we designed, engineered and
constructed the first generation of our proprietary drug manufacturing
equipment utilized in producing our investigational compound, LVT3.  We also
engineered and constructed the first ("GEN-1") and second generation ("GEN-2")
of our proprietary LVT3 drug deliver devices utilized in our viral
inactivation process.   After constructing and testing the equipment, we
commenced pre-clinical research of LVT3 in an independent laboratory setting.

          On March 29, 2004, we released pre-clinical research results that
utilized LVT3 and our GEN-2 technology.  These results demonstrated
substantial inactivation of four different infectious viruses, including: a
DNA and a RNA virus, both with simple lipid envelopes; a DNA virus with a
complex lipid envelope; and, a small, non-enveloped virus.  The research was
sponsored by LipidViro Tech and conducted at an independent laboratory. The
studies were performed in a variety of biological media chosen to represent
potential candidates for commercial products.

          Demonstrating antiviral efficacy in four differently structured
viruses is a milestone achievement for LipidViro and the Company's proprietary
GEN-2 technology. These studies were part of the Company's ongoing
pre-clinical research program designed to evaluate the efficacy and toxicity
of LVT3 and the Company's process. (See Item 6.)

          Most recently, the Company completed engineering and construction of
its third generation ("GEN-3") drug delivery device.  We have initiated study
of LVT3 utilizing the new GEN-3 technology to evaluate efficacy and toxicity
against various pathogens as compared to our GEN-1 and GEN-2 technologies.  We
have filed for patent protection covering our LVT3 drug production and GEN-1,
GEN-2 and GEN-3 drug delivery devices, and for proprietary methods utilized in
our viral inactivation process.  (See Item 6.)

ITEM 3 Controls and Procedures

     As of the end of the period covered by this Quarterly Report, we carried
out an evaluation, under the supervision and with the participation of our
President of the effectiveness of the design and operation of our disclosure
controls and procedures.  Based on this evaluation, our President concluded
that our disclosure controls and procedures are effective in timely alerting
them to material information required to be included in our periodic
Securities and Exchange Commission reports.  It should be noted that the
design of any system of controls is based in part upon certain assumptions
about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future
conditions, regardless of how remote.  In addition, we reviewed our internal
controls, and there have been no significant changes in our internal controls
or in other factors that could significantly affect those controls subsequent
to the date of their last evaluation.

                   PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
          ------------------

          None; not applicable.


Item 2.   Changes in Securities.
          ----------------------

          None; not applicable.

Item 3.   Defaults Upon Senior Securities.
          --------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
          ----------------------------------------------------

          See the Definitive Information Statement that was filed with the
Securities and Exchange Commission on July 23, 2003, and which is incorporated
herein by reference.  See Part II, Item 6.

Item 5.   Other Information.
          ------------------

          At a Board of Directors' meeting held on January 9, 2004, the
Company adopted new Bylaws, a copy of which is attached hereto and
incorporated herein by reference.  See Item 7.

          On January 19, 2004, Adina Hamik resigned as a Director and Chief
Operating Officer.  See Item 7.

Item 6.   Exhibits and Reports on Form 8-K.
          ---------------------------------

          (a)  Exhibits.

          31 302 Certification of Kenneth P. Hamik

          32 906 Certification

          (b)  Reports on Form 8-K.

          8-K/A Report dated August 19, 2003, and filed March 26, 2004
          regarding Certificate of Amendment to the Articles of
          Incorporation, Bylaws, Petition for Fairness Hearing, Agreement
          and Plan of Reorganization, Motion for Expedited Hearing, Petition
          for Fairness Hearing in the State of Nevada, Nevada Court Order
          Granting Petition of Fairness.

          8-K Report dated August 19, 2003, and filed September 9, 2003

          8-K Current Report of the Company dated June 24, 2003, which was
          previously filed with the Securities and Exchange Commission on
          June 27, 2003



                               SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Company has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                     LIPIDVIRO TECH, INC.


Date: 14 May, 2004                 By/s/Kenneth P. Hamik
      --------------                 -------------------
                                     Kenneth P. Hamik
                                     President and Director